|North American Banks Fund
||EPS - Basic
||Market Cap (m)
|Equity Investment Instruments
North American Banks Fund Share Discussion Threads
Showing 76 to 93 of 100 messages
|Last Updated: 10/23/2006
Exchange: TSX Venture
Current Share Price: $0.52
Shares Outstanding: 32.6 million
Shares Fully Diluted: 46.5 million
52 Week Range (Lo - Hi): $0.30 - 0.62
Market Capitalization: $16.952 million
SUBJECT: Toronto Resource Investment Conference Posted By: pyoing
Post Time: 9/25/2006 22:28
I attended the conference and listened to the Nam corporate presentation given by Tommy Cheng CEO.
Most of what Tommy spoke is already on their website, but there were a few additions that some may find useful.
- there will be a NI43-101 due out November.
- 2007: 10,000oz. gold to be poured, with an additional 5,000oz. from
newly acquired properties.
- US. OTC.BB listing is not being considered by NAM, but in the future
the company does want to graduate from the Frankfurt onto
Hong Kong exchange.
- over a $million in the kitty.
SUBJECT: RE: Toronto Resource Investment Conference Posted By: joemanner
Post Time: 9/25/2006 22:42
The conference is informative to me as they have some new exciting projects due to have news coming out soon.
I found out a new surge on projects on China after reading the Northern Miner issue on the China/ Mongolia. NAM is definitely among one of them as it has featured, not bad for a Company only listed for less than 6 months!
SUBJECT: RE: Toronto Resource Investment Conference Posted By: BillyMiner
Post Time: 9/28/2006 15:38
I spoke to the guys at the show as well.
NAM has poured 400 oz of gold already from the Majiahe Property and will most likely get about 2000 oz in total from that project this year. As Pyoing said, they will get another 10,000 oz next year. The newly acquired property will also have production. They have an amazing exploration property (Xuefeng Property) with huge potential and they are currently working on a 43-101 for it. I got the feeling that they are also looking at some other properties to acquire as well. This company has awesome potential for the short and long term.
I've got closing prices for NAM going back to 1994 if that's far enough for you.
Post your e-mail address and I'll forward it later in the week as I'm incommunicado after 2:30pm for the next 2 days.
|has nam been suspended? cant get any quotes on this and no trades.|
|short zyt has a pe of 60 !!
whoops edit. wrong thread :))|
|time to go short on NAM...target 5 quid, stop 600|
|time to go long on nam...target 7 quid, stop 550|
|After the great results and chart breakout the chairmans todger will be some size now..I saY GOOD ON HIM.|
|INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2001 for TCFKANA (The Company Formerly Known as Nycomed Amersham)
'.... HIGHLIGHTSSales up 13% to £783 million, earnings per share up 10% to 13.6pImaging sales up 13% to £458 million, driven by growing markets and focus on major disease areasAccelerated growth in portfolio of patented products: sales up 28% to £144 millionGrowth of unpatented products: sales up 10% to £174 millionAmersham Pharmacia Biotech sales up 13% to £325 millionDrug discovery sales up 9% to £71 million: good growth in proteomics, held back by sequencingContinued strong performance in separations, driven by growing sales of biopharmaceuticals and focus on the study of proteins: sales up 22% to £130 million ......'|
|Does "interesting short" mean "risky short"? :-)
I'd be very cautious about calling direction on this one right now - the signals are conflicting!!!
The short-term trend (since the last major move, for the purposes of this discussion!) is still up. The intraday high at 571 is just above the 570 of a week ago (same for the closing prices) - this means that there is a good chance of the uptrend continuing until it reaches resistance and there is no reason for this to suddenly reverse. I'd say there is a decent chance of a drop back to 500, but it's equally likely to test resistance again at 580 or even 600.
The medium term trend is downward, but given the entire market shot up in 1Q200 and down afterwards, there are few stocks that do not exhibit this pattern. If you think the market, in general, is going down, there are better vehicles to take positions with.
Haven't got my annotated charts here, but that's my tuppence worth for now!
I'm thinking it looks like an interesting short right now. Lower high and all that.|
|MM, are we still on the trading here, or is this one of the "late night confessions" threads! :-)
No, out of NAM - I moved my trailing stop in close when it struggled to break through 500. Got taken out on the way up to 522ish at the start of July. Very nice trade for me - the charting was perfect, entered at correct time, used my stops well, got taken out by my trailing stop. Lots of discipline for a change - don't know what went wrong, er right!
|SpiceBoy - you still short?|
|Cheers Brian, not often you get a well done on this BB :-)
500 is such a key level - if it drops below we're into freefall, but if it stays above it should recover. I'm still short but have a tight stop, so worst case I still make a good profit. The Merck p/w can't have helped but an interest rate cut will.
|Now it's getting intersting - down she goes!|
|OK, here's the story of the last 6 weeks from a NAM perspective...nothing - dull, Dull, DULL!
Sitting in the range 540ish - 570ish, some days it goes up a bit, some days it goes down a bit! It really needs to move decisively out of this range to indicate a clear direction. I'm still short, but if I wasn't I'd be waiting for a break either way. Really a close above 580 or below 530 would do it for me (although we did open at 581 and reach 586 a few days back, but I generally wait for a close to confirm direction...)
Agree about failing to break resistance previously, but on the other hand, it's a nice ascending triangle, which it looks to be breaking up out of today. I'd consider a break through 570, and ideally a bounce off it from the other side as pretty positive|
|now 5.80 and going well.Great company.|
|NYCOMED AMERSHAM ANNOUNCES FDA CLEARANCE AND LAUNCH OF ECHOSEED
'New Generation of Prostate Brachytherapy Seeds Strengthens Company's
Leadership Position in Seed Implant Therapy for Prostate Cancer
London, June 4, 2001-Nycomed Amersham (LSE:NAM; NYSE:NYE), the world leader in brachytherapy implants for prostate cancer announced it has received FDA clearance and all other regulatory approvals in the U.S. required to market
EchoSeed (Iodine-125), a new generation of brachytherapy seed that will
maximize patient care. EchoSeed's patented technology utilizes conventional
ultrasound imaging, to provide physicians with more information about seed
placement during the course of an implant procedure.
"EchoSeed represents the first true breakthrough in brachytherapy treatment
since the introduction of RAPID Strand in 1995 and will reinforce Nycomed
Amersham's leadership position in the U.S.," said John Jeans, President of
Nycomed Amersham Imaging's Therapy Products business. "EchoSeed was developed
after feedback from leading practitioners in prostate brachytherapy who wanted
more immediate visual information about seed placement during the course of a
prostate implant, using currently available imaging technology. Extensive
market research among physicians verified EchoSeed's strong market potential,"
added Mr. Jeans.
EchoSeed's patented grooved design in combination with conventional ultrasound
imaging allows the physician to view both the prostate gland and EchoSeed
during an implant procedure. The physician is able to see more of the seeds
during the implant procedure thus facilitating optimal placement into the
prostate. EchoSeed will be launched later today at the American Urological
Association Annual Meeting in Anaheim, California.
Nycomed Amersham is the world leader in brachytherapy implants, used to treat
prostate cancer. The company's product portfolio includes OncoSeed, (brand of
Iodine-125 prostate brachytherapy seeds) the world's leading prostate implant
seed for the treatment of prostate cancer and TheraSeed, the world's leading
palladium-103 brachytherapy seed. In addition, the company markets its
proprietary RAPID Strand ideally suited for the treatment of extraprostatic
extension of prostate cancer; (disease, that affects the area just outside the